Investigational Drug Information for QGC001
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for QGC001?
QGC001 is an investigational drug.
There have been 10 clinical trials for QGC001.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 25th 2020.
The most common disease conditions in clinical trials are Hypertension, Essential Hypertension, and Myocardial Infarction. The leading clinical trial sponsors are Quantum Genomics SA, Eurofins Optimed, and PRA Health Sciences.
There are three US patents protecting this investigational drug and forty-seven international patents.
Summary for QGC001
| US Patents | 3 |
| International Patents | 47 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2020-06-25) |
| Vendors | 13 |
Recent Clinical Trials for QGC001
| Title | Sponsor | Phase |
|---|---|---|
| Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH) | PRA Health Sciences | Phase 3 |
| Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH) | Quantum Genomics SA | Phase 3 |
| Firibastat in Treatment-resistant Hypertension | Quantum Genomics SA | Phase 3 |
Clinical Trial Summary for QGC001
Top disease conditions for QGC001
Top clinical trial sponsors for QGC001
US Patents for QGC001
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| QGC001 | See Plans and Pricing | Derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfonates) and compositions comprising the same | Institute National de la Sante et de la Recherche Medicale (Inserm) (Paris Cedex, FR) | See Plans and Pricing |
| QGC001 | See Plans and Pricing | Method for the preparation of (3S, 3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) | QUANTUM GENOMICS (Paris, FR) | See Plans and Pricing |
| QGC001 | See Plans and Pricing | Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) | QUANTUM GENOMICS (Massy, FR) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for QGC001
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| QGC001 | Austria | AT455097 | 2023-08-06 | See Plans and Pricing |
| QGC001 | Canada | CA2533432 | 2023-08-06 | See Plans and Pricing |
| QGC001 | Cyprus | CY1109950 | 2023-08-06 | See Plans and Pricing |
| QGC001 | Germany | DE602004025119 | 2023-08-06 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
